Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISCT 2021 | Importance of international harmonization in cell & gene therapies

Jaap Boelens • 26 May 2021

Jaap Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the importance of international harmonization and consensus within the field of cell and gene therapies and how this can help drive the field forward. Dr Boelens highlights the importance of harmonising the eligibility criteria, monitoring standards and outcome measures of early phase clinical trials to allow better comparison of data and to help with the earlier identification of therapeutic solutions most likely to succeed in later phase clinical trials. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.


Jaap Boelens has served as a consultant for: BlueRock, Omeros, Sanofi, Advanced Clinical, AvroBio, Race Oncology and Medexus.